Biotechnology company Macrocure has announced that the European Patent Office (EPO) intends to grant a European patent covering Marcocure's flagship product, CureXcell. The patent will be officially granted under an application titled "Activate Leukocyte Composition" and will provide patent coverage for CureXcell in Europe through March 2030.

CureXcell is a novel approach to treating hard-to-heal wounds by replenishing the imbalanced inflammatory environment in non-healing wounds with a broad array of functionally-active allogeneic immune cells. These cells are superficially injected into the wound bed, once a month, and release the necessary cytokines and growth factors for the wound to heal.

About 5,000 patients with various types and severities of hard-to-heal wounds have been treated in Israel. CureXcell has been approved for reimbursement by the Israeli Ministry of Health.

"The granting of a European patent for CureXcell is a significant milestone for MacroCure, which fits with our strategy to become a leader in the hard to heal wound treatment market in Europe," said Nissim Mashiach, president and CEO of Macrocure.

Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies.